Episode notes
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.
Launch Date: December 5, 2024
Release Date: December 5, 2024
Expiration Date: November 30, 2025
FACULTY
Aditya Bardia, MD, MPH, FASCO
Associate Professor, Medicine, Harvard Medical School